Results 181 to 190 of about 53,065 (244)
Archives of Internal Medicine, 1966 SINCE the early descriptions of the carcinoid syndrome, 1-4 it has been assumed that the associated hyperserotonemia is responsible for the symptoms and development of the cardiac lesions. These lesions, which appear mainly on the right side of the heart, are characterized by subendocardial proliferation of fibrous tissue resulting in thickening of the
Arnold Adicoff +2 more
openaire +4 more sources
Diagnosis and Treatment of Malignant Carcinoid Syndrome
JAMA: The Journal of the American Medical Association, 1975 To the Editor.— The article, "Diagnosis and Treatment of Malignant Carcinoid Syndrome," by Dr. A. L. Ureles (229:1346, 1974) contains several serious errors. In this letter I shall concentrate on those that have substantial patient-care implications. Documentation of the statements I shall make may be found in a recent textbook chapter1that will also ...
Robert J. Levine
openaire +3 more sources
Cushing's and Malignant Carcinoid Syndromes From Ovarian Neoplasm
Archives of Internal Medicine, 1965 Introduction THERE is a growing appreciation of the protean nature of the so-called carcinoid tumor in terms of site of origin, histological appearance, and capacity for hormone production. 1 In addition to the now widely recognized capacity of these tumors to produce the tryptophan metabolite, serotonin (5-HT), and the serotonin precursor, 5 ...
Montague Lane, Harold Brown
openaire +4 more sources
Malignant carcinoid syndrome: Survival in the octreotide LAR era
Journal of Clinical Oncology, 2005 4084 Background: Somatostatin analogues (SMSA) (octreotide) are effective in controlling excess hormonal symptoms in the majority of patients (pts) with carcinoid syndrome.
Y. Shyr, L. B. Anthony, T. Kang
openaire +3 more sources
Cutaneous Manifestations of the Malignant Carcinoid Syndrome
Annals of Internal Medicine, 1963 Charles E. Mengel
semanticscholar +4 more sources
Cutaneous manifestations of the malignant carcinoid syndrome [PDF]
Journal of the American Academy of Dermatology, 2004 Hazel Bell +3 more
openaire +3 more sources
The occurrence of malignant carcinoid syndrome in patients with carcinoid tumors.
Bratislavske lekarske listy, 2002 The carcinoid syndrome occurs in about 10% of patients with carcinoid tumors.The main objective of the present study was to determine the presence of the carcinoid syndrome in a group of patients with carcinoid tumor.35 pts with carcinoid tumors (group A--24 pts with metastatic disease, group B--11 pts after resection of the primary tumor with no ...
S, Kinova +7 more
openaire +2 more sources
Gastrointestinal carcinoids and the malignant carcinoid syndrome.
Surgery, gynecology & obstetrics, 1981 The records of 59 patients with gastrointestinal carcinoid tumors at The New York Hospital from 1948 to 1978 were reviewed. Forty-seven instances were diagnosed surgically; 12 were identified on autopsy specimens. The average age at diagnosis was 55.8 years. No association with duodenal ulcer or carcinoma could be made. The appendix was the mose common
H, Beaton, W, Homan, P, Dineen
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The malignant carcinoid syndrome
The American Journal of Digestive Diseases, 1966R. J. Gailitis
openaire +4 more sources
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
New England Journal of Medicine, 1986We studied the effects of a long-acting analogue of somatostatin (SMS 201-995, Sandoz) in 25 patients with histologically proved metastatic carcinoid tumors and the carcinoid syndrome.
L. Kvols +5 more
semanticscholar +1 more source